Press "Enter" to skip to content

The Future Of HIV Treatment Seems To Be Fuzzy Due To Ethics

Suddenly, an obstacle has arrived in the smooth path of the development of new ways of disease treatment. The Trump administration along with some anti-abortion officials and social conservatives has aimed at the huge project working on the development of HIV treatment that specifically requires fetal tissues.

The conflict raised by the conservatives against the research exhausting fetal tissues has generated the chaos in granting the agreement by National Institute of Health to the University of California, San Francisco for the legal continuation of the research.

From the last decade of the 20th century, U.S. FDA approved almost all the HIV therapies and NIH has provided the complete support in the research in which the UCSF laboratory and an affiliated institute have been included.

According to the information provided by the virologist, during the previous week, an official from the NIH contracting department has informed the principal investigator of the research at UCSF that the administration was terminating the seven-year agreement in the midway. And after five days, a notice was received by UCSF from the National Institute for Allergy and Infectious Diseases, which said that the administration would allow the research using fetal tissues for not more than 90 days.

The unexpected insecurity about the lab’s future has exploded as government’s health officials are reviewing whether the government should change its support of research including fetal tissue

In recent weeks, officials from the Health and Human Services Department have set meetings with various oppositions including antiabortionists, patients, advocates, and scientific societies to understand their viewpoints without declaring any decisions.

Trump, various social conservatives, and anti-abortion activists have been pressurizing administration to break the support for such research that utilizes tissue from unborn babies. However, there is no current substitute of fetal tissue usage, said by Irving Weissman, who is an inventor in stem cell research, Stanford University.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *